Current Development and Future Prospects in Chemotherapy of Tuberculosis

Overview

Journal Respirology

Specialty Pulmonary Medicine

Date 2010 Jun 16

PMID 20546189

Citations 21

Authors

Eric L Nuermberger

Melvin K Spigelman

Wing Wai Yew

Affiliations

Soon will be listed here.

Abstract

Although treatment of drug-susceptible tuberculosis (TB) under ideal conditions may be successful in >or=95% of cases, cure rates in the field are often significantly lower due to the logistical challenges of administering and properly supervising the intake of combination chemotherapy for 6-9 months. Success rates are far worse for multidrug-resistant and extensively drug-resistant TB cases. There is general agreement that new anti-TB drugs are needed to shorten or otherwise simplify treatment for drug-susceptible and multidrug-resistant/extensively drug-resistant-TB, including TB associated with HIV infection. For the first time in over 40 years, a nascent pipeline of new anti-TB drug candidates has been assembled. Eleven candidates from seven classes are currently being evaluated in clinical trials. They include novel chemical entities belonging to entirely new classes of antibacterials, agents approved for use against infections other than TB, and an agent already approved for limited use against TB. In this article, we review the current state of TB treatment and its limitations and provide updates on the status of new drugs in clinical trials. In the conclusion, we briefly highlight ongoing efforts to discover new compounds and recent advances in alternative drug delivery systems.

Citing Articles

Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?.

Maphalle L, Michniak-Kohn B, Ogunrombi M, Adeleke O Children (Basel). 2022; 9(8).

PMID: 36010011 PMC: 9406656. DOI: 10.3390/children9081120.

Application of Lipid-Based Nanocarriers for Antitubercular Drug Delivery: A Review.

Buya A, Witika B, Bapolisi A, Mwila C, Mukubwa G, Memvanga P Pharmaceutics. 2021; 13(12).

PMID: 34959323 PMC: 8708335. DOI: 10.3390/pharmaceutics13122041.

Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against .

Palucci I, Maulucci G, De Maio F, Sali M, Romagnoli A, Petrone L Front Immunol. 2020; 10:3042.

PMID: 32038614 PMC: 6992558. DOI: 10.3389/fimmu.2019.03042.

Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.

Lee B, Clemens D, Silva A, Dillon B, Maslesa-Galic S, Nava S Nat Commun. 2017; 8:14183.

PMID: 28117835 PMC: 5287291. DOI: 10.1038/ncomms14183.

Rifamycins, Alone and in Combination.

Rothstein D Cold Spring Harb Perspect Med. 2016; 6(7).

PMID: 27270559 PMC: 4930915. DOI: 10.1101/cshperspect.a027011.

References

Alcala L, Ruiz-Serrano M, Garcia de Viedma D, Diaz-Infantes M, Marin-Arriaza M, Bouza E . In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother. 2002; 47(1):416-7. PMC: 148996. DOI: 10.1128/AAC.47.1.416-417.2003. View

Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R . Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol. 2007; 3(6):323-4. DOI: 10.1038/nchembio884. View

Chan E, Iseman M . Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis. 2008; 21(6):587-95. DOI: 10.1097/QCO.0b013e328319bce6. View

Nuermberger E, Rosenthal I, Tyagi S, Williams K, Almeida D, Peloquin C . Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother. 2006; 50(8):2621-5. PMC: 1538692. DOI: 10.1128/AAC.00451-06. View

Williams K, Stover C, Zhu T, Tasneen R, Tyagi S, Grosset J . Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother. 2008; 53(4):1314-9. PMC: 2663111. DOI: 10.1128/AAC.01182-08. View

Flores A, Parsons L, Pavelka M . Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. Microbiology (Reading). 2005; 151(Pt 2):521-532. DOI: 10.1099/mic.0.27629-0. View

Fox W, Ellard G, Mitchison D . Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999; 3(10 Suppl 2):S231-79. View

Johnson J, Hadad D, Boom W, Daley C, Peloquin C, Eisenach K . Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006; 10(6):605-12. View

Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J . Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother. 2005; 56(5):968-74. DOI: 10.1093/jac/dki319. View

10.

Ashtekar D, Nagrajan K, Vishvanathan N, Bhatt A, Rittel W . In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1993; 37(2):183-6. PMC: 187635. DOI: 10.1128/AAC.37.2.183. View

11.

Nicolau D . Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008; 47 Suppl 1:S32-40. DOI: 10.1086/590064. View

12.

Rosenthal I, Williams K, Tyagi S, Peloquin C, Vernon A, Bishai W . Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med. 2006; 174(1):94-101. PMC: 1862756. DOI: 10.1164/rccm.200602-280OC. View

13.

Conte Jr J, Golden J, Kelley M, Zurlinden E . Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents. 2005; 26(6):449-56. DOI: 10.1016/j.ijantimicag.2005.08.015. View

14.

Gordin F, Chaisson R, Matts J, Miller C, de Lourdes Garcia M, Hafner R . Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American.... JAMA. 2000; 283(11):1445-50. DOI: 10.1001/jama.283.11.1445. View

15.

Chambers H, Turner J, Schecter G, Kawamura M, Hopewell P . Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother. 2005; 49(7):2816-21. PMC: 1168716. DOI: 10.1128/AAC.49.7.2816-2821.2005. View

16.

Nuermberger E, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, OBrien R . Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004; 170(10):1131-4. DOI: 10.1164/rccm.200407-885OC. View

17.

Yew W, Chan C, Chau C, Tam C, Leung C, Wong P . Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000; 117(3):744-51. DOI: 10.1378/chest.117.3.744. View

18.

Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V . Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother. 2006; 51(3):1011-5. PMC: 1803154. DOI: 10.1128/AAC.00898-06. View

19.

Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K . Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem. 2008; 283(37):25273-25280. DOI: 10.1074/jbc.M803899200. View

20.

Ahmad Z, Peloquin C, Singh R, Derendorf H, Tyagi S, Ginsberg A . PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother. 2010; 55(1):239-45. PMC: 3019674. DOI: 10.1128/AAC.00849-10. View